marked.bio

Company

Jiangsu Hengrui

22 active trials that select patients by a biomarker on marked.bio, across 6 biomarkers; 9 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

HRS-4642 4adebrelimab 4trastuzumab rezetecan 4SHR-A1904 4HRS-7058 3SHR-A2009 2aumolertinib 2fulzerasib 1garsorasib 1glecirasib 1camrelizumab 1regorafenib 1fruquintinib 1trastuzumab deruxtecan 1cetuximab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

22 of 38 trials shown

  1. A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

    Not yet recruiting Phase 3 Jiangsu Hengrui Started 2026Primary completion 2028-05 NCT07601048

    HRS-7058fulzerasibgarsorasibglecirasib

    …enter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Stand…

    KRAS G12CKRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment

  2. A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2032-11 NCT07183189

    SHR-A2009aumolertinib

    …lly confirmed locally advanced, metastatic, or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  3. HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer

    Recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2029-04 NCT07232875

    HRS-4642

    …ne as First-line Treatment for Advanced or Metastatic Pancreatic Adenocarcinoma Harboring KRAS G12D Mutation

    KRAS G12DKRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting

  4. A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2026-12 NCT06671379

    SHR-A2009platinum-based dual-agent chemotherapy

    A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  5. A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

    Not yet recruiting Phase 2/3 Jiangsu Hengrui Started 2024Primary completion 2028-10 NCT06335355

    adebrelimabpemetrexedcarboplatincamrelizumab

    Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-03-28Non-squamous Non-small Cell Lung Cancer

  6. A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

    Recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2026-02 NCT06430437

    trastuzumab rezetecanpemetrexedpaclitaxelcarboplatincisplatin

    Subjects with central laboratory- confirmed functional HER2 mutations

    HER2 (ERBB2) activating mutationNon-Small Cell Lung Cancer With HER2- Mutations

  7. SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2027-09 NCT06649292

    SHR-A1904paclitaxeldocetaxelirinotecan

    6. positive CLDN18.2 expression in tumor tissue;

    Claudin 18.2 expressionSecond-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  8. Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2026-04 NCT06199973

    trastuzumab rezetecantrifluridine/tipiracilregorafenibfruquintinib

    …reatment with oxaliplatin, 5-fluorouracil (such as 5-FU, Capecitabine) , irinotecan (DMMR/MSI-H subjects also need anti-PD-1/PD-L1 antibody treatment failure) ;

    MSI-H / dMMRAdvanced Colorectal Cancer

  9. SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2023Primary completion 2026-03 NCT05814354

    trastuzumab rezetecancapecitabineeribulingemcitabinepaclitaxelnab-paclitaxel

    Low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested).

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer

  10. An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

    Recruiting Phase 2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07589569

    HRS-7058

    …y of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.

    KRAS G12CPancreatic Cancer

  11. An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07806058

    adebrelimabHRS-7172 + AG;HRS-4642

    …ocally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing.

    KRAS G12CKRAS G12DPancreatic Cancer

  12. A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

    Recruiting Phase 2 Jiangsu Hengrui Started 2026Primary completion 2028-06 NCT07497386

    trastuzumab rezetecantrastuzumab deruxtecan FDA EU

    …Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer

  13. A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

    Recruiting Phase 2 Jiangsu Hengrui Started 2026Primary completion 2030-12 NCT07450976

    SHR-A1904

    CLDN18.2 positive expression;

    Claudin 18.2 expressionBiliary Tract Cancer

  14. A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1/2 Jiangsu Hengrui Started 2024Primary completion 2025-12 NCT06385678

    HRS-4642adebrelimabSHR-9839pemetrexedcisplatincarboplatincetuximab

    With unresectable locally advanced or metastatic solid tumors harbouring with KRAS G12D mutation confirmed by central laboratory testing.

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors

  15. Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

    Not yet recruiting Phase 1/2 Jiangsu Hengrui Started 2022Primary completion 2027-07 NCT05503888

    aumolertinib

    …Innovative Drugs in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer With EGFR Mutation

    EGFR exon 19 deletion / L858RStatus may be outdated, last updated 2022-08-17Relapsed or Advanced Non-small Cell Lung Cancer

  16. A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2022Primary completion 2026-05 NCT05277168

    SHR-A1904

    Positive expression of Claudin 18.2 (\>= 50% of cells with 2+ or 3+ expression, either from fresh or archival tissue) is requ…

    Claudin 18.2 expressionAdvanced Solid Tumors

  17. A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

    Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-12 NCT07142980

    HRS-7172 Tablets

    A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

    KRAS G12CKRAS G12DAdvanced Solid Tumors Harboring RAS Mutations or Amplifications

  18. A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

    Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-12 NCT07189949

    HRS-2329 Tablet

    A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

    KRAS G12CKRAS G12DAdvanced Solid Tumors Harboring RAS Mutations or Amplifications

  19. Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

    Recruiting Phase 1 Jiangsu Hengrui Started 2025Primary completion 2028-05 NCT07134998

    HRS-6093

    Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors

  20. A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

    Recruiting Phase 1 Jiangsu Hengrui Started 2024Primary completion 2026-06 NCT06383871

    HRS-7058

    …inetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation

    KRAS G12CAdvanced Malignant Tumour

  21. SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

    Recruiting Phase 1 Jiangsu Hengrui Started 2024Primary completion 2027-12 NCT06350006

    SHR-A1904adebrelimabCAPOX

    6. positive CLDN18.2 expression in tumor tissue;

    Claudin 18.2 expressionCLDN18.2-positive Advanced Solid Tumor

  22. Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1 Jiangsu Hengrui Started 2022Primary completion 2024-06 NCT05533463

    HRS-4642

    Histologically confirmed diagnosis of advanced solid tumor harbouring with KRAS G12D mutation

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors